Soluble CD23 in human immunodeficiency virus type 1 infected patients

Area of Science:

• Immunology
• Virology
• Biochemistry

Background:

• Human immunodeficiency virus (HIV) infection is a global health concern.
• Soluble CD23 (sCD23) is a marker implicated in immune regulation.
• Understanding immune markers in HIV infection is crucial for disease management.

Purpose of the Study:

• To measure sCD23 levels in HIV-infected patients across different disease stages.
• To compare sCD23 levels between HIV patients and healthy controls.
• To investigate the correlation between sCD23 levels and disease progression in HIV.

Main Methods:

• Immunoradiometric assay used to quantify sCD23 levels.
• Peripheral blood mononuclear cells (PBMCs) stimulated with phytohemagglutinin (PHA).
• Plasma sCD23 levels analyzed in HIV patients (CDC groups II and IV) and healthy controls.

Main Results:

• Higher sCD23 values observed in supernatants of stimulated PBMCs from some asymptomatic (group II) and AIDS (group IV) HIV patients compared to controls.
• Plasma sCD23 levels did not show statistically significant differences between HIV groups and healthy individuals.
• A subset of HIV patients (6% in group II, 16.7% in group IV) exhibited sCD23 levels above 2 U/ml.
• Elevated sCD23 levels were found in patients with secondary infectious diseases.

Conclusions:

• While not statistically significant across groups, elevated sCD23 levels were detected in a portion of HIV-infected individuals, particularly those with AIDS.
• The presence of secondary infections correlated with increased sCD23 values.
• sCD23 may serve as a potential indicator of immune activation or disease severity in specific HIV patient subgroups.